Introduction
The liver performs major functions of the organism, which include uptake of amino acid, lipids, carbohydrate and vitamins, and their subsequent storage, conversion and release into the blood and bile. This organ is also the principal target involved in the biotransformation of chemicals with its capacity to convert hydrophobic compounds into water-soluble products that can be secreted readily from the body. A number of drugs and other xenobiotics are potentially hepatotoxic either directly or more frequently after biological activation leading to the formation of chemically reactive metabolites or generation of reactive oxygen species.
Drug-induced liver injury is broadly classified into intrinsic and idiosyncratic types. While the former is dose-dependent and predictable the latter is not directly dose-dependent, unpredictable and occurs in rare patients only. Various genetic and non-genetic factors are thought to cause predisposition to idiosyncratic drug-induced liver injury that accounts for the majority of hepatotoxicity associated with medication use, probably by altering the expression level of target genes. Over 1000 drugs and herbal products have been reported to cause this type of liver injury (Biour et al., 2004; Stickel et al., 2005) . There are presently no suitable preclinical models to study idiosyncratic drug-induced liver injury.
A large inter-individual variability has long been observed in the expression and corresponding activities of many genes related to drug metabolism and drug induction in either human liver or primary human hepatocytes (Morel et al., 1990; LeCluyse et al., 2000; Madan et al., 2003) . These results have been confirmed and extended by analysing responses to chemicals across the entire transcriptome in primary human hepatocytes (Liguori et al., 2005; Goyak et al., 2008; Lambert et al., 2009; Rogue et al., 2011) . By contrast, although a variety of genes related to other hepatic functions can be the target of hepatotoxic drugs, much less information exists about inter-individual variability in their basal expression.
In the present study we compared the whole transcriptome of six human hepatocyte populations in primary culture and human differentiated HepaRG cells. Recent studies using whole genome microarrays have indeed confirmed the great similarity between primary human hepatocytes and HepaRG cells in the responsiveness of genes related to chemical metabolism (Jennen et al., 2010; Lambert et al., 2009 ). We show that, whereas variations in the percentages of expressed genes were low, huge inter-individual differences in the transcripts levels were observed between the primary human hepatocyte populations and that
HepaRG cells expressed most of the genes active in human hepatocytes. Primary human hepatocytes. Human hepatocytes from 6 adult donors undergoing resection for primary and secondary tumors, were provided by Biopredic International (Rennes, France) (Supplemental Table 1 ). They were obtained by collagenase perfusion of histologically normal liver fragments and freshly seeded at a density of 17×10 4 cells/cm 2 in 6-well dishes in a Williams' E medium supplemented with 10% FCS, 100 units/μl penicillin, 100 μ g/ml streptomycin, 1 μ g/ml insulin, 2 mM glutamine and 1 μ g/ml bovine serum albumin. The medium was discarded 12h after seeding and cells were thereafter maintained in serum-free medium supplemented with 10 -7 M hydrocortisone hemisuccinate.
HepaRG cells. The cells were obtained from Biopredic International at passages 14 and 16.
For the present studies, they were first seeded at a density of 2.6×10 4 cells/cm 2 in 6-well dishes in a Williams' E medium supplemented with 10% FCS, 100 units/µl penicillin, 100 μ g/ml streptomycin, 5 μ g/ml insulin, 2 mM glutamine and 5×10 −5 M hydrocortisone hemisuccinate. After two weeks of culture, they were shifted to the same culture medium supplemented with 2% dimethylsulfoxide (DMSO) for two further weeks in order to reach maximum functional activities. Media were renewed every 2-3 days. Differentiated HepaRG cell cultures were composed of both hepatocyte-like and biliary epithelial-like cells (about 50% of each type) (Cerec et al., 2007 
Numbers of expressed genes
Only genes exhibiting an intensity signal superior to 200 associated with a p-value <0.01 were considered to be expressed in primary human hepatocytes and HepaRG cells (Table 1B) .
Indeed, this cut-off removed most of the non-hepatic genes. Moreover, since HepaRG cells are derived from a liver tumor of a female patient, we looked for expression of genes known to be located on chromosome Y. However, numerous genes located on this chromosome are also found on other chromosomes, e.g. Interleukin 9 Receptor (IL9R) and CD99, and were, as expected, also expressed in HepaRG cells. Nevertheless, few genes were not expressed in HepaRG cells or in hepatocytes from the unique female patient (donor #6). One example was the Dead box protein 3, Y linked (DDX3Y) gene whose intensity signal was much lower than the background signal ( Figure 2A ).
The total number of genes expressed in human hepatocytes varied from 8335 to 9501 genes depending on the donor (Table 1B) . A maximum variation of 14% was observed between donors #1 and #2. The number of genes commonly expressed between donors for pairwise comparison of any two sets of the data varied from 7842 and 9030 genes (Table 2C) .
Noticeably, 7780 genes were common to the 6 donors, whereas 10095 genes were expressed in at least one donor.
The number of genes expressed in HepaRG cells was analyzed at two different passages; it reached 11888 and 12036 genes at passages 14 and 16, respectively. Among them, 11691
were common (Table 1B) . Comparison of the numbers of genes expressed in human hepatocytes revealed that 8168 to 9262 genes were expressed in common in at least one human hepatocyte donor and HepaRG cells, representing 81 to 92 % of the total genes expressed in at least one human hepatocyte donor (Table 1C) .
variability. Thus, genes involved in phase I drug biotransformation such as CYP2A6, CYP3A4 and CYP2E1, were markedly differentially expressed between all donors. The lowest expression values of these genes were usually found in donors #5 and #6. As an example, CYP3A4 was 31-fold less expressed in donor #6 than in donor #1. Other CYPs, such as CYP2D6, CYP1A2 and CYP2C19, were also expressed in all six donors with expression levels similarly lower in donors #5 and #6 than in others (Supplemental Table 2 ).
Noteworthy, the prototypical nuclear receptor, the constitutive androstane receptor gene (CAR also known as NR1I3), was more expressed in donors #1, #2, #3 and #4 (Supplemental Table   2 ). Likewise, the CAR-dependent responsive gene, CYP2C9, was much more expressed in donors #1 to #4 than in donors #5 and #6 (Supplemental Figure 1) .
Expression of many genes encoding various phase II conjugating enzymes, including several UDP-glucuronosyltransferases (UGT), such as UGT2A3 and UGT2B10, and glutathione Stransferases (GST), such as GSTA1 and GSTA2, also markedly varied from one donor to another. Moreover, GSTM1, which is known to be expressed in only 50% of the individuals, was not detected in 2 out of the 6 donors (i.e. donors #1 and #3). Various transporters were also differentially expressed across the donors; they included multidrug resistance protein (MDR) 1, multi-drug resistance associated protein (MRP) 3 and 4, and ATP binding cassette subfamily G member 5 (ABCG5). The bile salt efflux pump (BSEP also known as ABCB11) was detected in donor #1 only. Interestingly, CYP7A1 as well as ABCG5, both involved in cholesterol metabolism, were dramatically expressed in donor #1. By contrast, CYP8B1 was expressed at similar levels in all hepatocyte populations (Supplemental Table 2 ).
Most genes involved in other hepatic functions, such as carbohydrate and lipid metabolisms, and the urea cycle, were less differentially expressed between primary human hepatocyte populations than those related to xenobiotic metabolism. Nevertheless, few genes involved in carbohydrate [glucose-6-phosphatase (G6Pc), glycogen synthase 2 (GYS-2), hexokinase 1 Table 4 ) and responsible for the discrimination between the two cell models. A great number of genes involved in DNA repair and the cell cycle were always more expressed in HepaRG cells while genes involved in xenobiotic metabolism, complement and coagulation cascade and inflammatory processes, were frequently expressed at higher levels in primary hepatocytes. The less expressed xenobioticrelated genes in HepaRG cells included genes encoding some CYPs (e.g. CYP2D6, CYP2E1), conjugating enzymes (e.g. GSTP1, UGT1A6) and membrane transporters involved in excretion of endogenous and/or exogenous compounds (e.g. ABCG5). However, ABCB11
(BSEP) and ABCB4 (MDR3), two genes encoding bile acid transporters, were at least 1.5-and 3-fold more expressed in HepaRG cells than in human and 341 hepatocytes, with the exception of donor #1. The basolateral transporter ABCC3 (MRP3) was also much more expressed in HepaRG cells than in human hepatocytes. Less than 350 genes expressed in at least one human hepatocyte population were not detected in HepaRG cells; they included some phases I and II genes, such as CYP2C18, GSTP1 and GSTM3 (Supplemental Tables 2   and 3 ).
Importantly, HepaRG cells expressed 29% more genes than the human hepatocyte populations, in particular genes involved in the cell cycle, such as cyclin B1 (CCNB1), cyclin D1 (CCND1), cell division cycle (CDC) 2 and 6, as well as genes involved in focal adhesion and transcriptional activity, such as signal transducer and activator of transcription 3
Since these transformed cells exhibit a trisomic chromosome 7 (Gripon et al., 2002) we examined whether some of the genes located on chromosome 7 were selectively expressed.
Among the 1500 genes located on this chromosome approximately 110 genes, including IL6, carnitine O-octanoyltransferase (CROT) and SLC25A40, were found to be expressed in HepaRG cells only (Table S3) . Interestingly, the cytokeratin 19 (KRT19), known as a stemness and biliary cell marker, was dramatically more expressed in HepaRG cells than in human hepatocytes ( Figure 2 ). Another biliary cell marker, the α 6-integrin (Couvelard et al., 1998) , was expressed in both HepaRG cells and human hepatocytes but was 2-fold higher in the former.
Is a basal gene expression level predictable of an unusual response to a hepatotoxic drug?
To date, gene expression changes induced by chemicals have been mostly focused on genes related to xenobiotic metabolism and inter-individual responses were found to be more variable than were the corresponding global basal gene expression profiles (Goyak et al., 2008; Rakhshandehroo et al., 2009; Rogue et al., 2011) . Moreover, a higher induction level was frequently observed for CYPs with a low basal expression or activity (Guillouzo and Guguen-Guillouzo, 2008) . We postulated that an abnormal basal expression of some target genes could lead to an abnormal response to a hepatotoxic drug in some patients and could help to explain an idiosyncratic toxicity. Four out of the six human hepatocyte populations analysed in the present study have been previously used to investigate changes in the transcriptome profiles induced by four PPAR agonists, e.g. two glitazones (troglitazone and rosiglitazone) and two glitazars (muraglitazar and tesaglitazar) (Rogue et al., 2011) .
Comparison of basal expression levels of target and non target genes (this study) and their PPAR-induced fold changes in the same culture conditions, showed that basal gene expression levels could greatly influence the level of response to the treatment, particularly with the hepatotoxic drug troglitazone (Table 2 ). For instance, pyruvate dehydrogenase kinase isozyme 4 (PDK4), an enzyme involved in fatty acid and glucose oxidation, was up-and down-regulated with 20 µM troglitazone in the two hepatocyte populations which had the lowest and the highest basal expression levels respectively. Similarly, CYP7A1, implicated in bile synthesis, as well as BSEP and ABCG5, both involved in bile acid secretion, showed 8.6-, 2.5-and 1.5-fold decrease respectively, with troglitazone, that has been reported to cause cholestasis, in donor #4 hepatocytes which had the highest gene expression levels. In addition, the heme oxygenase 1 gene (HMOX1) involved in oxidative stress and inflammation,
frequently associated with cholestasis, was also highly induced by troglitazone treatment (9.7-fold) in the same donor #4, which had the lowest basal gene expression. No such strong relationships between basal transcript levels of target genes and their drug-induced fold changes were evidenced with the three other hepatocyte populations treated with troglitazone or with the four hepatocyte populations treated either with rosiglitazone which has caused only very rare cases of hepatotoxicity or with the two glitazars which have induced only nonhepatic toxicities. No obvious relationship between basal transcript levels of target genes and their drug-induced fold changes was also observed in HepaRG cells treated with either troglitazone or the three other PPAR agonists (Table 2) .
Comparative microarray and qPCR data
Microarray and qPCR results were compared for several genes in each hepatocyte population (Supplemental Table 5 ). 
Discussion
In the present study, we report the first analysis of the genome-wide expression profiles of human hepatocytes from several donors and the differentiated human HepaRG cell line.
Based on a cut-off intensity signal of 200 and a technical p-value < 0.01, 7780 out of 20232 genes present on the microarrays were found to be expressed in the 6 human hepatocyte populations analysed. These genes included both annotated and non annotated genes. If most human genes were represented on the microarrays, few important ones were however lacking, In contrast with the low inter-individual qualitative differences not exceeding 14% in the 6 tested human hepatocyte populations, huge variations were observed in the transcript levels of a number of genes, especially among those related to drug, carbohydrate, amino-acid and lipid metabolisms. Indeed, many genes involved in xenobiotic metabolism, such as CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, GSTT1 and UGT2B7, were highly differentially expressed across individuals particularly between donors #5 and #6. It is well 
T r a n s p l a n t 1 3 : 2-day human hepatocyte cultures from 4 donors (#2, #4, #5 and #6) and HepaRG cells were previously treated for 24h with 20 µM of troglitazone (TRO), 50 µM of rosiglitazone (ROSI), 50 µM of muraglitazar or 300 µM of tesaglitazar (TESA) (Rogue et al., 2011) and the fold changes obtained for various genes are displayed in this table. The four compounds were synthesized by the Servier Chemical Department and t he two color -microarray technology was used to obtain these fold changes (Rogue et al., 2011) . The same RNA samples were used in the present study for obtaining basal gene expression values (hybridizations were performed as described in the material and methods section). In bold abnormal basal expression levels and corresponding fold changes after troglitazone treatment of some genes in the human hepatocytes from donor # 4.
